Sunrays
Project Purpose
As soon as approved and manufactured, the delivery of Covid-19 vaccines will be urgent, requiring speed, reliability, security, and special care that air cargo is offering. Like for any other medical treatment, the air cargo industry is committed to ensure the safe delivery of the vaccines but the unprecedent urgency and scale of this logistics challenge necessitate global and local strategies to be defined and each logistics provider to be prepared.
Project Objective(s)
The aim of Project Sunrays was to provide timely and verified information for the pharma industry and air cargo stakeholders to support them in their planning and decision-making process.
Project Status And Key-takeaways
This project was finalized in February 2021.
The optimal transportation of the vaccines can be translated into the most efficient, safest, widely distributed vaccine possible. This will require collaboration along the entire supply chain, open communication, and early planning to make sure the transportation goes smoothly. The entire global supply chain is now working on this challenge.
All industry partners need to continue working together with full transparency to meet shippers’ needs and expectations: integrity, speed, security, reliability, and transparency.
The project identified areas of priorities:
- Strengthening industry collaboration
- Ensuring high level of security
- Improving visibility
- Removing barriers
- Ramping-up air cargo capabilities
- Covid-19 Vaccine Air Logistics Requirements
- Covid-19 Vaccine Air Transportation and Handling Recommended Practices
- Air Cargo Community Initiatives
PROJECT
SUPPORT AND
COLLABORATION.
Steering Committee:
- Brussels Airport Company
- Changi Airport Group
- Edmonton International Airport
- Flexport
- Miami International Airport
- Neutral Air Partner
- Sats
- Turkish Airlines
- 4Advice, Change Horizon and Mediconed (external consultants)
Active engagement of vaccines manufacturers (Pharma.Aero members and non-members):
- Biontech
- GSK
- Johnson & Johnson
- MSD
- Pfizer
- Sanofi